ClinicalTrials.Veeva

Menu

Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk

C

Creighton University

Status

Enrolling

Conditions

Osteopenia
Type 1 Diabetes
Fractures, Bone
Bone Loss

Treatments

Procedure: Transilial bone biopsy

Study type

Observational

Funder types

Other

Identifiers

NCT05701254
1425624-3

Details and patient eligibility

About

Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefits to society because the knowledge gained from this study may help better understand the effects of diabetes on bone health

Full description

The investigators will enroll 40 female, postmenopausal, patients with T1DM, fracturing or non-fracturing, who are age 50 and over, and have had diabetes for more than ten years. The investigators will perform 2 transiliac (hip bone) biopsies on each subject, one for mechanical testing, tissue analysis of AGEs, enzymatic crosslinks and bone tissue-bound water in cortical bone, and the other for histomorphometry and high-resolution 3D imaging in trabecular bone. A matched, non-diabetic, healthy control will be enrolled at the time each T1DM is enrolled.

Enrollment

80 estimated patients

Sex

Female

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Criteria for enrollment of female diabetics

  1. No chronic disease diagnoses that may affect bone, as confirmed by the PI.
  2. Normal clinical history, physical, and clinical laboratory exam (except for usual complications of a 10+-year diabetic, i.e., ~minimal neuropathy or retinopathy, known, but asymptomatic mild vascular disease, etc.)
  3. Glomelular Filtration Rate (GFR) >45 ml/min (Renal Association lower limit for "mild" kidney failure).
  4. Willingness to sign a consent form.
  5. Willingness to undergo a transilial bone biopsy incision that yields 2 bone specimens.
  6. No abnormalities in clinical blood chemistry measurements (small, age-related decreases in GFR, will be permitted).
  7. Caucasian

Criteria for each non-diabetic subject, compared to their matched diabetic:

  1. Dual-energy x-ray absorptiometry (DXA) measures (BMD, gm/cm) must be within +/- 15% in total hip.
  2. Body mass index (BMI) must be within +/-10%.
  3. Age must be within +/- 5 years.
  4. Caucasian

Exclusion criteria

  1. Women who have had Type 1 diabetes for less than 10 years.
  2. Non-insulin dependent Type 1 diabetic.
  3. Less than 50 years old.
  4. Less than 5 years post menopausal.

Trial design

80 participants in 2 patient groups

Type 1 Diabetics
Description:
All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
Treatment:
Procedure: Transilial bone biopsy
Non-Type 1 Diabetics
Description:
All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
Treatment:
Procedure: Transilial bone biopsy

Trial contacts and locations

1

Loading...

Central trial contact

Laura Armas, M.D.; Adam Hornig

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems